SK Biopharmaceuticals Co., Ltd. (326030.KS)
- Previous Close
88,500.00 - Open
91,300.00 - Bid 91,600.00 x --
- Ask 91,700.00 x --
- Day's Range
90,600.00 - 93,700.00 - 52 Week Range
72,600.00 - 130,000.00 - Volume
353,958 - Avg. Volume
195,781 - Market Cap (intraday)
7.205T - Beta (5Y Monthly) 0.94
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Aug 6, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
140,937.50
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication, for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder. The company has collaborative research agreement with Korea Institute of Radiological and Medical Sciences for discovering and developing radiopharmaceutical drug candidates using an alpha-particle emitting radioisotope, actinium-225, for potential cancer treatments; and research collaboration agreement with ProEn Therapeutics for accelerating expansion of oncology research and pipeline for radiopharmaceuticals. SK Biopharmaceuticals Co., Ltd. was founded in 1993 and is headquartered in Seongnam-si, South Korea. SK Biopharmaceuticals Co., Ltd. operates as a subsidiary of SK Inc.
www.skbp.comRecent News: 326030.KS
View MorePerformance Overview: 326030.KS
Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 326030.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 326030.KS
View MoreValuation Measures
Market Cap
6.93T
Enterprise Value
6.79T
Trailing P/E
28.79
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
12.66
Price/Book (mrq)
12.69
Enterprise Value/Revenue
12.40
Enterprise Value/EBITDA
67.43
Financial Highlights
Profitability and Income Statement
Profit Margin
43.96%
Return on Assets (ttm)
6.84%
Return on Equity (ttm)
50.72%
Revenue (ttm)
547.6B
Net Income Avi to Common (ttm)
240.74B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
324.49B
Total Debt/Equity (mrq)
32.14%
Levered Free Cash Flow (ttm)
33.48B